Hiromi Hayashi

Mrs. Hiromi Hayashi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
HHHiromi Hayashi
Hiromi Hayashi
NMNaoto Miyazaki
Naoto Miyazaki
TKTakuya Kawakami
Takuya Kawakami
SIShusaku Izumi
Shusaku Izumi
KYKazuhiro Yoshinaga
Kazuhiro Yoshinaga
Background: FimH inhibitors are anticipated to serve as preventive therapeutics against urinary tract infections. Consequently, multiple inhibitors—predominantly D-mannose derivatives—have been synthesized, and their binding affinities (determined by dissociation coefficient; KD) to FimH have been examined in vitro. Nevertheless, the amounts of most of these synthetic compounds that reach the urinary tract after oral administration in humans have not been investigated. D-mannose (Man) and its analog, 1-Deoxymannose (DM), have already been reported to show KD values against FimH. Therefore, this study aimed to estimate the post-oral ingestion of FimH inhibitory potentials of DM and Man in the urinary tract. Methods: Six participants were given single 1 g doses of DM and Man in a crossover test. The sample concentrations in urine were measured 8 h after ingestion. Results: DM levels increased rapidly after oral intake; contrarily, Man was detected in the urine before administration, with no notable increase post-ingestion. The peak concentration ranges of Man and DM in urine were 2.15–22.9 μg/mL and 665–57,804 μg/mL, respectively, which are 66.3–707 and 3600–31,200 times that of KD, respectively. Conclusions: These results indicate that DM as a supplement is an orally active FimH inhibitor in the human urinary tract. Conversely, d-mannose is expected to exert comparatively milder inhibition.

5 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
KTKenichi Tanabe
Kenichi Tanabe
ITIkuma Tanaka
Ikuma Tanaka
HHHiromi Hayashi
Hiromi Hayashi
KYKazuhiro Yoshinaga
Kazuhiro Yoshinaga
SNSadako Nakamura
Sadako Nakamura
Background/Objectives: We hypothesized that orally ingested 1,5-anhydro-D-mannitol (AM) would be absorbed from the gut but poorly metabolized, and it may have low fermentability by gut microbiota based on the breath hydrogen test. Methods: We used a dual-model approach in this study. In animal experiments, AM was administered orally to male Wistar rats. In a randomized, three-way crossover trial (UMIN000054040), 15 healthy young adults consumed a single 5 g dose of AM, mannose, or fructooligosaccharide (FOS). Primary outcome was breath hydrogen concentrations; secondary outcomes included plasma AM, blood glucose concentration, and urinary AM excretion. Results: After ingestion of 5 g AM in humans, the 14 h area under the curve for breath hydrogen excretion was markedly lower after AM than that after FOS ingestion (p < 0.05). Plasma AM peaked at 1 h, whereas blood glucose remained unchanged from baseline. Approximately 30% of ingested AM was excreted unchanged in urine within 24 h. Results of animal experiments were similar to those in humans. Fecal excretion in AM was confirmed to be minimal, accounting for ~1% of the administered dose within 24 h in rats. Conclusions: These findings indicate that AM is potentially a low-energy carbohydrate.

2 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HHHiromi Hayashi
Hiromi Hayashi
NMNaoto Miyazaki
Naoto Miyazaki
TKTakuya Kawakami
Takuya Kawakami
SIShusaku Izumi
Shusaku Izumi
KYKazuhiro Yoshinaga
Kazuhiro Yoshinaga
Background: FimH inhibitors are anticipated to serve as preventive therapeutics against urinary tract infections. Consequently, multiple inhibitors—predominantly D-mannose derivatives—have been synthesized, and their binding affinities (determined by dissociation coefficient; KD) to FimH have been examined in vitro. Nonetheless, their preventive efficacy in humans, including those governed by the rate of delivery of orally administered drugs to the urinary tract and the KD values. Therefore, this study aimed at investigating the post-ingestion FimH inhibitory effects of DM and D-mannose in the urinary tract. Six participants were administered single 1-g doses of the samples in a crossover test. The D-mannose analog, 1-Deoxymannose (DM), reportedly exhibits an identical KD to FimH as D-mannose. Methods: To estimate the post-ingestion FimH inhibitory effects of DM and D-mannose in the urinary tract, six participants were administered single 1-g doses of the samples in a crossover test. The sample concentrations in urine were measured 8 h after ingestion. Results: DM levels increased rapidly after oral intake; contrarily, D-mannose was detected in the urine before administration with no notable increase post-ingestion. The peak concentration ranges of D-mannose and DM in urine were 2.15–22.9 μg/mL and 665–57,804 μg/mL, respectively, which are 66.3–707 and 3,600–31,200 times that of KD, respectively. Conclusions: These results indicate that DM as a supplement is an orally active FimH inhibitor with substantial efficacy in the human urinary tract. Conversely, D-mannose is expected to exert comparatively milder effects.